These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 18983225)
1. Efficacy, safety, and current applications of brimonidine. Fudemberg SJ; Batiste C; Katz LJ Expert Opin Drug Saf; 2008 Nov; 7(6):795-9. PubMed ID: 18983225 [TBL] [Abstract][Full Text] [Related]
2. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. García-López A; Paczka JA; Jiménez-Román J; Hartleben C BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295 [TBL] [Abstract][Full Text] [Related]
4. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Goñi FJ; Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288 [TBL] [Abstract][Full Text] [Related]
5. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616 [TBL] [Abstract][Full Text] [Related]
6. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406 [TBL] [Abstract][Full Text] [Related]
7. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918 [TBL] [Abstract][Full Text] [Related]
8. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension. Frampton JE Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399 [TBL] [Abstract][Full Text] [Related]
9. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. Katz LJ J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359 [TBL] [Abstract][Full Text] [Related]
10. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R; J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698 [TBL] [Abstract][Full Text] [Related]
11. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. LeBlanc RP Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370 [TBL] [Abstract][Full Text] [Related]
12. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components. Konstas AG; Katsimpris IE; Kaltsos K; Georgiadou I; Kordelou A; Nelson LA; Stewart WC Eye (Lond); 2008 Nov; 22(11):1391-7. PubMed ID: 17571086 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma. Joshi SR; Akat PB; Ramanand JB; Ramanand SJ; Karande VB; Jain SS Indian J Ophthalmol; 2013 Dec; 61(12):765-7. PubMed ID: 24008808 [TBL] [Abstract][Full Text] [Related]
14. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Schuman JS Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247 [TBL] [Abstract][Full Text] [Related]
16. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients. Nguyen QH; Earl M J Ocul Pharmacol Ther; 2009 Dec; 25(6):541-4. PubMed ID: 20028261 [TBL] [Abstract][Full Text] [Related]
17. [Fixed combinations of glaucoma medications]. Călugăru D; Călugăru M Oftalmologia; 2008; 52(3):23-31. PubMed ID: 19149113 [TBL] [Abstract][Full Text] [Related]
18. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. Javitt JC; Schiffman RM J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373 [TBL] [Abstract][Full Text] [Related]
19. Brimonidine/Timolol: a viewpoint by Francisco J. Goñi. Goñi FJ Drugs Aging; 2006; 23(9):762-3. PubMed ID: 17020402 [No Abstract] [Full Text] [Related]
20. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Cantor LB; Safyan E; Liu CC; Batoosingh AL Curr Med Res Opin; 2008 Jul; 24(7):2035-43. PubMed ID: 18534052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]